Integra LifeSciences (IART) Set to Announce Earnings on Monday

Integra LifeSciences (NASDAQ:IART - Get Free Report) will announce its earnings results before the market opens on Monday, November 4th. Analysts expect the company to announce earnings of $0.39 per share for the quarter. Persons that are interested in registering for the company's earnings conference call can do so using this link.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last posted its quarterly earnings data on Monday, July 29th. The life sciences company reported $0.63 earnings per share for the quarter, beating analysts' consensus estimates of $0.62 by $0.01. The firm had revenue of $418.20 million for the quarter, compared to analyst estimates of $413.07 million. Integra LifeSciences had a net margin of 1.51% and a return on equity of 14.07%. Integra LifeSciences's quarterly revenue was up 9.7% on a year-over-year basis. During the same period last year, the firm posted $0.71 EPS. On average, analysts expect Integra LifeSciences to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Integra LifeSciences Stock Performance

Shares of IART stock traded up $0.37 during mid-day trading on Monday, hitting $19.32. The stock had a trading volume of 482,114 shares, compared to its average volume of 1,087,948. Integra LifeSciences has a fifty-two week low of $16.81 and a fifty-two week high of $45.42. The company has a debt-to-equity ratio of 1.17, a current ratio of 3.39 and a quick ratio of 2.10. The company's 50-day simple moving average is $18.79 and its 200-day simple moving average is $24.92. The firm has a market cap of $1.52 billion, a PE ratio of 37.90, a PEG ratio of 0.65 and a beta of 1.09.

Analyst Ratings Changes

Several equities analysts have issued reports on the company. Citigroup dropped their target price on Integra LifeSciences from $20.00 to $16.00 and set a "sell" rating on the stock in a research report on Tuesday, October 1st. Truist Financial decreased their target price on shares of Integra LifeSciences from $26.00 to $21.00 and set a "hold" rating on the stock in a research report on Monday, October 14th. Bank of America cut their price target on shares of Integra LifeSciences from $26.00 to $18.00 and set an "underperform" rating for the company in a report on Monday, October 7th. BTIG Research raised shares of Integra LifeSciences from a "sell" rating to a "neutral" rating in a report on Monday, October 7th. Finally, Morgan Stanley increased their target price on shares of Integra LifeSciences from $24.00 to $27.00 and gave the company an "underweight" rating in a report on Monday, July 15th. Three equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of $26.50.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.